ABEONA THERAPEUTICS INC. (modificare)
Versiunea de la data 29 septembrie 2024 00:07
, 29 septembrie 2024The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).
Admin (discuție | contribuții) (Pagină nouă: Pagina dedicata companiei ABEONA THERAPEUTICS INC. listata cu simbolurile US.ABEO, US.ABEOc ==Descriere companie== Abeona Therapeutics Inc. (https://abeonatherapeutics.com/) is a clinical-stage biopharmaceutical company that develops gene and cell therapies for life-threatening rare genetic diseases. The Company’s lead clinical programs consist of EB-101, which is an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102, wh...) |
(The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).) |
||
| Linia 2: | Linia 2: | ||
==Descriere companie== | ==Descriere companie== | ||
Abeona Therapeutics Inc. (https://abeonatherapeutics.com/) is a clinical-stage biopharmaceutical company that develops gene and cell therapies for life-threatening rare genetic diseases. The Company’s lead clinical programs consist of EB-101, which is an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102, which is an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101, which is an AAV-based gene therapy for Sanfilippo syndrome type B (MPS IIIB). It is focused on to develop additional AAV-based gene therapies designed to treat ophthalmic and other diseases and AAV-based gene therapies using the AIM capsid platform that has a license from the University of North Carolina at Chapel Hill and internal AAV vector research programs. | [[Abeona Therapeutics]] Inc. (https://abeonatherapeutics.com/) is a clinical-stage biopharmaceutical company that develops gene and cell therapies for life-threatening rare genetic diseases. The Company’s lead clinical programs consist of EB-101, which is an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102, which is an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101, which is an AAV-based gene therapy for Sanfilippo syndrome type B (MPS IIIB). It is focused on to develop additional AAV-based gene therapies designed to treat ophthalmic and other diseases and AAV-based gene therapies using the AIM capsid platform that has a license from the University of North Carolina at Chapel Hill and internal AAV vector research programs. | ||
==Grafic actiuni companie== | ==Grafic actiuni companie== | ||